161 related articles for article (PubMed ID: 34787835)
1. Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors.
Nakamae M; Nakamae H; Hashimoto M; Koh H; Nakashima Y; Hirose A; Hino M
Int J Hematol; 2022 Mar; 115(3):329-335. PubMed ID: 34787835
[TBL] [Abstract][Full Text] [Related]
2. [Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors].
Matsumura I
Rinsho Ketsueki; 2018; 59(1):13-26. PubMed ID: 29415932
[TBL] [Abstract][Full Text] [Related]
3. [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
Miyazaki S
Rinsho Ketsueki; 2021; 62(8):1024-1028. PubMed ID: 34497188
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.
Malkan UY; Haznedaroglu IC
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5493-5506. PubMed ID: 37401285
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up.
Aghel N; Lipton JH; Atenafu EG; Kim DDH; Delgado DH
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):870-878.e1. PubMed ID: 28803825
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors.
Ross DM; Arthur C; Burbury K; Ko BS; Mills AK; Shortt J; Kostner K
Intern Med J; 2018 Feb; 48 Suppl 2():5-13. PubMed ID: 29388307
[TBL] [Abstract][Full Text] [Related]
7. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
9. Endothelial function in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors is not related to cardiovascular risk assessed by the Systematic Coronary Risk Estimation 2 algorithm.
Szczepanek E; Marczyk B; Chukwu O; Chlopicki S; Sacha T
Pol Arch Intern Med; 2024 Jun; 134(6):. PubMed ID: 38572907
[TBL] [Abstract][Full Text] [Related]
10. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
Chiwata M; Itonaga H; Sato S; Hashimoto M; Fujioka M; Kasai S; Sakamoto H; Toriyama E; Nakashima J; Kamijo R; Kitanosono H; Kobayashi Y; Horai M; Taguchi M; Matsuo M; Makiyama J; Takasaki Y; Matsuo E; Horio K; Ando K; Sawayama Y; Taguchi J; Kawaguchi Y; Tsushima H; Imanishi D; Imaizumi Y; Yoshida S; Jo T; Nonaka H; Moriuchi Y; Nagai K; Yokota KI; Hata T; Miyazaki Y
Intern Med; 2021 Jul; 60(14):2207-2216. PubMed ID: 33612681
[TBL] [Abstract][Full Text] [Related]
12. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
13. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease.
Leong D; Aghel N; Hillis C; Siegal D; Karampatos S; Rangarajan S; Pond G; Seow H
Heart; 2021 Apr; 107(8):667-673. PubMed ID: 33419879
[TBL] [Abstract][Full Text] [Related]
16. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
[TBL] [Abstract][Full Text] [Related]
17. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Breccia M; Colafigli G; Molica M; Alimena G
Expert Opin Drug Saf; 2016; 15(4):525-33. PubMed ID: 26799331
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
19. Lifelong TKI therapy: how to manage cardiovascular and other risks.
Mauro MJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):113-121. PubMed ID: 34889360
[TBL] [Abstract][Full Text] [Related]
20. New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Almeida AG; Almeida A; Melo T; Guerra L; Lopes L; Ribeiro P; Duarte M; Mota A; Fontes-Carvalho R
Rev Port Cardiol (Engl Ed); 2019 Jan; 38(1):1-9. PubMed ID: 30686651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]